#4-49E. Navigating Live Vaccines: Early Rotavirus Immunization in TNFi-Exposed Infants (Rheumatology, 2026)

Are you hesitant about the optimal timing of live vaccines for infants exposed to biologic therapies during pregnancy? This episode reviews a population-based cohort study analyzing the safety of administering the live rotavirus vaccine before six months of age to infants exposed to tumor necrosis factor inhibitors (TNFi) in utero. The most crucial clinical takeaway is that early rotavirus vaccination does not increase the risk of diarrhea-associated healthcare events, even among infants with late-pregnancy or high placental-transfer TNFi exposure. However, when critically appraising these findings, listeners must note the study's reliance on administrative claims data, meaning that mild diarrhea cases not requiring an outpatient or emergency medical visit might be underrepresented. For physicians, this study is highly impactful because it substantiates recently updated rheumatology guidelines with robust, large-scale safety data. It directly empowers pediatricians and rheumatologists to confidently recommend early rotavirus immunization, preventing severe gastrointestinal infections without compromising the health of these vulnerable newborns.

Citation: Flatman LK, Vinet É. Diarrhoea events in offspring exposed to tumour necrosis factor inhibitors and rotavirus vaccine: a population-based cohort study. Rheumatology. 2026. DOI: 10.1093/rheumatology/keag161

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.